Related Experiment Video
Updated: Jun 22, 2026

Exploring Protein-Glycan Interactions: Advances in Nuclear Magnetic Resonance
Published on: August 26, 2025
Characterization of the interaction between serum mannan-binding protein and nucleic acid ligands
Natsuko Nakamura1, Motohiro Nonaka, Bruce Yong Ma
1Research Center for Glycobiotechnology, Ritsumeikan University, Shiga 525-8577, Japan.
Abstract:
Serum MBP, also known as MBL, is a C-type lectin that is known to be a soluble host defense factor involved in innate immunity. It has been well established that dying microbes and apoptotic cells release highly viscous DNA that induces inflammation and septic shock, and apoptotic cells display fragmented DNA on their surfaces. However, PRRs that mediate the recognition and clearance of free DNA and fragmented DNA in apoptotic cells have not been characterized clearly. Although MBP was reported recently to bind DNA as a novel ligand, binding characterization and the recognition implications have not been addressed yet. In this study, we show that MBP can bind DNA and RNA in a calcium-dependent manner from a variety of origins, including bacteria, plasmids, synthetic oligonucleotides, and fragmented DNA of apoptotic cells. Direct binding and competition studies indicate that MBP binds nucleic acids via its CRD to varying degrees and that MBP binds dsDNA more effectively than ssDNA and ssRNA. Furthermore, we reveal that the MBP-DNA complex does not trigger complement activation via the MBP lectin pathway, and the lectin pathway of complement activation is required for MBP-mediated enhancement of phagocytosis of targets bearing MBP ligands and that MBP can recognize the fragmented DNA presented on apoptotic cells. Therefore, we propose that the MBP lectin pathway may support effective recognition and clearance of cellular debris by facilitating phagocytosis, possibly through immunomodulatory mechanisms, thus preventing autoimmunity.
Insights
Serum mannose-binding protein (MBP) binds DNA and RNA, enhancing phagocytosis of cellular debris. This pathway may prevent autoimmunity by aiding in the clearance of apoptotic cells and microbial DNA.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Serum mannose-binding protein (MBP) is a C-type lectin crucial for innate immunity.
- Dying cells and microbes release DNA, triggering inflammation and septic shock.
- Recognition mechanisms for free and fragmented DNA in innate immunity are not fully understood.
Purpose of the Study:
- To characterize the binding of MBP to DNA and RNA.
- To elucidate the role of MBP in the recognition and clearance of DNA from apoptotic cells and microbes.
- To investigate the implications of MBP-nucleic acid binding for innate immune pathways.
Main Methods:
- Calcium-dependent binding assays using various DNA and RNA sources.
- Direct binding and competition studies to assess MBP-nucleic acid interactions.
- Analysis of complement activation and phagocytosis assays involving MBP-DNA complexes.
Main Results:
- MBP binds DNA and RNA in a calcium-dependent manner, with preference for dsDNA.
- MBP-DNA complexes do not activate complement via the lectin pathway.
- MBP enhances phagocytosis of targets, recognizing fragmented DNA on apoptotic cells.
Conclusions:
- MBP binds nucleic acids via its CRD, playing a role in innate immune recognition.
- The MBP lectin pathway facilitates phagocytosis of cellular debris and microbial DNA.
- This pathway may prevent autoimmunity by promoting effective clearance of DNA and apoptotic cells.
Related Concept Videos
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...

